Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Atypon full text link Atypon Free PMC article
Full text links

Actions

Share

.2010 Apr 13;107(15):6982-7.
doi: 10.1073/pnas.1002472107. Epub 2010 Mar 29.

Modulation of mismatch repair and genomic stability by miR-155

Affiliations

Modulation of mismatch repair and genomic stability by miR-155

Nicola Valeri et al. Proc Natl Acad Sci U S A..

Abstract

Inactivation of mismatch repair (MMR) is the cause of the common cancer predisposition disorder Lynch syndrome (LS), also known as hereditary nonpolyposis colorectal cancer (HNPCC), as well as 10-40% of sporadic colorectal, endometrial, ovarian, gastric, and urothelial cancers. Elevated mutation rates (mutator phenotype), including simple repeat instability [microsatellite instability (MSI)] are a signature of MMR defects. MicroRNAs (miRs) have been implicated in the control of critical cellular pathways involved in development and cancer. Here we show that overexpression of miR-155 significantly down-regulates the core MMR proteins, hMSH2, hMSH6, and hMLH1, inducing a mutator phenotype and MSI. An inverse correlation between the expression of miR-155 and the expression of MLH1 or MSH2 proteins was found in human colorectal cancer. Finally, a number of MSI tumors with unknown cause of MMR inactivation displayed miR-155 overexpression. These data provide support for miR-155 modulation of MMR as a mechanism of cancer pathogenesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
hMLH1,hMSH2, andhMSH6 are direct targets of miR-155. (A) Locations of the target sites of miR-155 in the 3′ UTRs and/or the CDS of the indicated genes (see alsoFig. S1). The base position is counted from the first nucleotide in the CDS. (B) Colo-320 DM cells were transfected with the phRL-SV40 construct as a control and either the luciferase construct WT or MUT-155 and with premiR-155 or premiR control. After 24 h, dual luciferase assays were performed. *P < 0.005 relative to premiR control.
Fig. 2.
Fig. 2.
Overexpression of miR-155 decreases the expression of MLH1, MSH2, and MSH6 in CRC cells. Colo-320 DM cells were transfected with premiR-155, premiR control, or siRNA against selected genes for 48 h. (A) Transfection efficiency was confirmed by real-time PCR. miR-155 expression was normalized to the expression of RNU44. Error bars represent SEM. *P < 0.001 (n = 3). (B) miR-155 exerts a posttranscriptional effect on MMR core proteins. mRNA expression of indicated genes was normalized to that of vinculin. Error bars represent SEM.*P < 0.05 compared with control premiR (n = 3). (C) Representative blot of Western blot analysis along with the mean and SEM of three independent experiments. *P < 0.005 compared with control premiR.
Fig. 3.
Fig. 3.
Stable clones with overexpression of miR-155, indicating the functional effect of miR-155 overexpression on CRC cell lines. MMR proficient Colo-320 DM cells were stably infected with a lentiviral vector overexpressing miR-155 (Colo-155) or an empty vector (Colo-empty). (A) miR-155 expression assessed by Northern blot analysis, with MV-411 cells used as positive controls. (B) Representative Western blot analysis results, along with mean ± SEM of three independent experiments. *P < 0.05 relative to controls. (C) mRNA expression of selected genes assessed by real-time PCR (normalized to vinculin). Error bars represent SEM. *P < 0.05 (n = 3). (D) Microsatellite analysis of Colo-155 and Colo-empty cells using the BAT-26 and BAT 25 (mononucleotide repeats) and D17S250 (dinucleotide repeat) markers. Size markers are given at the top of the panel.
Fig. 4.
Fig. 4.
miR-155 expression is inversely related to MLH1 and MSH2 in CRC tissues. (A) Paraffin-embedded, formalin-fixed CRC tissues were incubated with LNA-probe anti–miR-155 or scrambled probe and IHC antibodies against MSH2 and MLH1. Representative photographs were captured with the Nuance system software (Ventana Medical System Inc.), with staining positive for both miR-155 and MSH2 or MLH1 shown. Blue and red staining identifies miR-155 and the target protein, respectively. No colocalization of miR-155 and MLH1 or MSH2 in the same cell nest is seen. (B) RNA and proteins extracted from fresh frozen human colorectal tissue. miR-155 expression was assessed by real-time PCR, and MMR protein expression was assessed by Western blot analysis. CRC with up-regulation (>2-fold) of miR-155 expression and down-regulation of MMR protein expression are shown. A strong correlation between the loss of hMLH1 and hMSH2 expression and miR-155 expression was increased by >3-fold in tumor compared with adjacent normal tissue (red line). Samples with an miR-155 cancer/normal ratio <3-fold displayed an uncertain effect on MMR expression.
Fig. 5.
Fig. 5.
miR-155 expression in hMLH1-negative tumors. miR-155 expression was assessed by in situ hybridization on paraffin-embedded tissues. (A) CR-78 cancer tissue (with unknown causes of MLH1 loss) showing strong miR-155 expression (large arrow), with stroma (small arrow) negative for miR-155 expression. (B) CR-79 tissue (MLH1 loss due to promoter methylation) showing faint expression of miR-155 only in inflammatory cells (large arrow), with no signal detected in cancer tissue (small arrow).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Friedberg EC, et al. DNA Repair and Mutagenesis. Washington, DC: American Society of Microbiology; 2006. 2nd Ed.
    1. Kolodner RD, Mendillo ML, Putnam CD. Coupling distant sites in DNA during DNA mismatch repair. Proc Natl Acad Sci USA. 2007;104:12953–12954. - PMC - PubMed
    1. Acharya S, Foster PL, Brooks P, Fishel R. The coordinated functions of the E. coli MutS and MutL proteins in mismatch repair. Mol Cell. 2003;12:233–246. - PubMed
    1. Drummond JT, Genschel J, Wolf E, Modrich P. DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSalpha/hMutSbeta ratio and reduces the efficiency of base-base mismatch repair. Proc Natl Acad Sci USA. 1997;94:10144–10149. - PMC - PubMed
    1. Cannavo E, et al. Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair. Cancer Res. 2005;65:10759–10766. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Atypon full text link Atypon Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp